Centene (CNC) is trading higher in the latest session after a fresh bullish sell-side action: Wells Fargo raised its price target on Centene to $41 from $30 and maintained its Equal Weight rating. The price-target lift is acting as a near-term catalyst for the shares as investors re-engage with the name after a volatile period for managed care and Centene’s own outlook reset.

With the stock still well below prior-cycle levels, incremental shifts in analyst framing can have an outsized impact, particularly when the debate centers on how quickly profitability can normalize in 2026 and beyond. The target increase signals a more constructive valuation view even without a full-throated rating change, which can be enough to draw in tactical buyers and drive a relief move.

Centene has been working to rebuild confidence following its prior guidance disruption, and investors have been focused on the durability of its margin profile across Medicaid and ACA Marketplace lines. The company reported full-year 2025 results and provided 2026 guidance on Feb. 6, 2026, which remains the anchor for forward estimates while the market watches for evidence of better pricing discipline, medical cost control, and execution on plan-year dynamics.

Traders will be watching for additional price-target changes from other firms, any commentary tied to ACA Marketplace risk/morbidity and Medicaid rate adequacy, and whether the move attracts continued buying into the close. Upcoming datapoints that can reinforce—or fade—today’s rally include management updates on utilization trends, state-level Medicaid rate actions, and any incremental guidance refinement as 2026 progresses.